Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332427 | 1.00 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL12702562 | 0.84 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL30173140 | 0.83 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL19968864 | 0.83 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL12702726 | 0.83 | CDK1 (0.63) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL25014486 | 0.83 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL25973358 | 0.83 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL21511169 | 0.80 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL21126195 | 0.76 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBP2RX7 | |
| SCHEMBL15921702 | 0.76 | P2RX7 (0.46) | P2RX7CDK1YTHDC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Pfizer Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141402-A1 | PURINE DERIVATIVES | ADORA3, ADORA1, HPRT1 | PI4KA 3909/4885PI4K2B 3781/4885PI4K2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.